Short Interest Update on Inovio Pharmaceuticals (INO)

Inovio Pharmaceuticals (INO) : The short interest in Inovio Pharmaceuticals (INO) has changed with an increase of 362,305 shares and the open interest is 2.7%. From 13,415,103 short positions on Jul 29, 2016, the shorts increased to 13,777,408 shares by August 15, 2016. There are 8 more days left for the expiry and the daily trading volume of the stock is 1,784,267 shares. The total interest of shorts is 20.2% of the shares available to the public. The short interest information was released on Wednesday Aug 24th after the market close.

Inovio Pharmaceuticals (NASDAQ:INO): The stock opened at $9.14 on Wednesday but the bulls could not build on the opening and the stock topped out at $9.24 for the day. The stock traded down to $8.50 during the day, due to lack of any buying support eventually closed down at $8.57 with a loss of -6.24% for the day. The stock had closed at $9.14 on the previous day. The total traded volume was 1,636,132 shares.


In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the Director of INOVIO PHARMACEUTICALS, INC., Collins Morton had purchased shares worth of $91,300 in a transaction dated on June 28, 2016. A total of 10,000 shares were purchased at a price of $9.13 per share. The information is based on open market trades at the market prices.Option exercises are not covered.

Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovios immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.